RT Journal Article
SR Electronic
T1 What role will ‘gliptins’ play in glycemic control?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 305
OP 310
VO 75
IS 4
A1 Bloomgarden, Zachary
A1 Drexler, Andrew
YR 2008
UL http://www.ccjm.org/content/75/4/305.abstract
AB The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levels of incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.